PDCD1 and hepatocellular carcinoma: Although the clinical trial of anti-programmed cell death-1 (PD-1) monotherapy failed to show a significant difference in the survival of patients with advanced HCC compared with conventional MTAs, synergic effects of the combination of different kinds of agents can be expected in several ongoing clinical trials of ICI-based therapy.